Predictive Oncology Inc. (POAI)
NASDAQ: POAI · Real-Time Price · USD
0.9600
-0.0300 (-3.03%)
At close: Jun 13, 2025, 4:00 PM
0.9602
+0.0002 (0.02%)
After-hours: Jun 13, 2025, 7:37 PM EDT
Predictive Oncology Revenue
Predictive Oncology had revenue of $110.31K in the quarter ending March 31, 2025, with 2,170.69% growth. This brings the company's revenue in the last twelve months to $1.73M, up 24.17% year-over-year. In the year 2024, Predictive Oncology had annual revenue of $1.62M, down -0.24%.
Revenue (ttm)
$1.73M
Revenue Growth
+24.17%
P/S Ratio
3.46
Revenue / Employee
$72,053
Employees
24
Market Cap
8.57M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.62M | -3.88K | -0.24% |
Dec 31, 2023 | 1.63M | 122.24K | 8.12% |
Dec 31, 2022 | 1.51M | 84.78K | 5.97% |
Dec 31, 2021 | 1.42M | 168.41K | 13.45% |
Dec 31, 2020 | 1.25M | -159.29K | -11.28% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
POAI News
- 2 days ago - Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp - GlobeNewsWire
- 18 days ago - Court Denies Renovaro Motion for an Expedited Trial in July - GlobeNewsWire
- 23 days ago - AI Meets Genomics: Predictive Oncology Breakthrough Coincides with Regeneron's $256M 23andMe Acquisition - GlobeNewsWire
- 25 days ago - Predictive Oncology Inc. Issues Shareholder Letter Titled, "Revolutionizing Medicine: AI-Driven Biomarker and Drug Discovery for Precision Health" - GlobeNewsWire
- 4 weeks ago - Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary - GlobeNewsWire
- 3 months ago - Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries - GlobeNewsWire